Title:  Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

December 14, 11:00 AM



  • Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, USA
  • Antonio González-Martín, MD, Clinica Universidad de Navarra, Spain
  • Ignace Vergote, MD, UZ Leuven, Belgium



  • Patient-specific and disease-specific factors that influence the prioritization of different PARP inhibitors – Dr. Matulonis
  • Role of PARP inhibitor maintenance therapy in newly diagnosed ovarian cancer - Dr. Gonzalez-Martin
  • PARP inhibitor-related adverse event identification and management – Dr. Vergote
  • Future directions for PARP inhibitor therapy in frontline ovarian cancer – panel discussion